{"slideshow_credits": null, "snippet": "The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector.", "abstract": "AstraZeneca agrees to buy majority stake in cancer drug developer Acerta Pharma for $4 billion.", "section_name": "Business Day", "print_page": "5", "document_type": "article", "byline": {"person": [{"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 1, "organization": ""}], "original": "By CHAD BRAY"}, "web_url": "http://www.nytimes.com/2015/12/18/business/dealbook/astrazeneca-to-acquire-majority-stake-in-acerta-pharma.html", "lead_paragraph": "The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector.", "headline": {"main": "AstraZeneca to Acquire Majority Stake in Acerta Pharma", "print_headline": "AstraZeneca to Acquire Control of a Cancer Drug Developer"}, "_id": "5672827538f0d82eed76c55e", "word_count": "395", "multimedia": [{"height": 126, "url": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 376, "url": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "376"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-12-18T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Acerta Pharma BV", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "AstraZeneca PLC", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3"}, {"name": "organizations", "value": "Pfizer Inc", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "5"}, {"name": "glocations", "value": "Great Britain", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}